Opioid Prescriptions Drop 15% as MAPS Registration Increases

Media Contact: LARA Communications 517-335-LARA (5272)
Email: mediainfo@michigan.gov

June 18, 2019‚Äč - The number of opioids dispensed in Michigan decreased in 2018 as more prescribers participated in the Michigan Automated Prescription System (MAPS). Compared to 2017, opioid prescriptions dispensed fell by 15 percent while the overall number of schedule 2-5 controlled substance prescriptions decreased by 11.5 percent. During the same time period, the state saw the MAPS program registration rate, which includes prescribers, pharmacists and delegate users, increased by more than 134 percent.

 

2017

2018

Percentage Change

MAPS Registration Rate  (Prescribers, pharmacists and delegate users)

29,148

68,328

+134.4%

Opioid Prescriptions Dispensed

9,670,789

8,223,103

-15%

Schedule 2-5 Controlled Substances Dispensed

19,943,203

17,642,901

-11.5%


The Dept. of Licensing and Regulatory Affairs (LARA) released these findings in conjunction with the 2018 Drug Utilization Report. The report outlines dispensing data by prescriber, dispenser, and patient levels through data collected by MAPS.

“MAPS has played a critical role in both combatting the opioid epidemic here in Michigan and in ensuring patients who need prescription drugs have access to them,” said Gov. Whitmer. “As leaders, we have a responsibility to help patients get the care they need and raise awareness on the opioid crisis and the damaging effects it has had on our families and our economy. I’m eager to continue working with LARA to ensure the health and safety of people across the state.”

LARA works with Appriss Health to administer NarxCare, an analytics and care management solution that automatically analyzes MAPS data while providing an interactive visualization of usage patterns to help identify potential risk factors to reinforce our prevention efforts. LARA’s recent efforts and improvements include:

  • Working with health professionals to integrate MAPS NarxCare analytics with Electronic Medical Records and the Pharmacy Dispensation System throughout Michigan.
  • The development of the nation’s first study evaluating the effectiveness of NarxCare. Appriss’s Michigan Implementation and Evaluation analyzes Narxcare risk scores and shows a decline in patients with a high potential to abuse prescription drugs.
  • Partnering with Appriss to utilize machine learning and artificial intelligence to increase efficiencies in compliance monitoring.

“As a result of our partnerships with the health care community, MAPS has become an invaluable tool for licensed professionals to use as they make prescribing decisions for their patients,” said LARA Director Orlene Hawks. “This decrease demonstrates that we are on the right track and must remain committed to providing state-of-the-art resources to Michigan prescribers and dispensers.”

MAPS – which launched with the PMP AWARxE platform in April 2017 – provides prescribers with a user-friendly portal, making it more efficient for practitioners to obtain information regarding controlled substances and schedule 2-5 drugs that have been dispensed to patients. Prescribers include dentists, physicians (M.D. and D.O.), podiatrists, optometrists, veterinarians, physician’s assistants with practice agreements and advanced practice registered nurses under delegation. Public Acts 248 and 249 of 2018 require prescribers of schedule 2-5 controlled substances to be registered with MAPS. Additionally, all prescribers are required to check MAPS before prescribing a controlled substance in a quantity that exceeds a 3-day supply.

The MAPS system provides users with state-of-the-art tools, including:

  • The Prescription Monitoring Program (PMP) AWARxE platform, which has the fastest response time in the drug monitoring industry. Record lookups are completed in seconds.
  • A dashboard that provides patient alerts, recent request history and the ability to maintain delegate user activity within the prescriber’s main account.   
  • Patient report requests which include seamless interstate data sharing. Patient reports include prescription history, prescriber and dispenser information that can all be provided in a complete summary.

 

 

2017

2018

Percentage Change

Units Dispensed (i.e., tablets, milliliters)

1,264,366,171

1,051,128,244

-16.9%

Days Supply Dispensed 

495,249,159

441,954,046

-10.8%

Total Opioid MME

7,960,705,895

6,272,733,819

-21.2%

 

Corresponding to the drop in controlled substance prescription are double-digit percent drops in units dispensed (i.e. tablets, milliliters) and total opioid morphine milligram equivalents (MME) from 2017 to 2018.

Additionally, seven specific controlled substances – including commonly abused hydrocodone and oxycodone – were dispensed at significantly lower numbers in 2018.
 

 

2017

2018

Percentage Change

Alprazolam 2 mg

6,939,880

5,118,689

-26.2%

Alprazolam 1 mg

34,379,472

27,849,498

-19%

Hydrocodone/Acetaminophen 10 mg-325mg

151,080,925

118,239,581

-21.7%

Hydrocodone/Acetaminophen 7.5 mg-325mg

84,705,294

66,741,785

-21.2%

Carisoprodol 350 mg

7,808,190

4,905,115

-37.2%

Oxycodone 30 mg

12,306,723

9,456,126

-23.2%

Promethazine w/Codeine

28,579,490

15,971,635

-44.1%

 

For more information on MAPS, visit Michigan.gov/MiMAPSInfo.

Learn the facts about opioids and find help at Michigan.gov/opioids.

Connect with us image

Facebook logoTwitter BirdYouTube IconLARA IconBPL dot image